Chondroprotective drugs in degenerative joint diseases

Rheumatology

Volumn 45, Issue 2, 2006, Pages 129-138

  Verbruggen, Gust ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chondroprotection; DMOADs; IL 1; Osteoarthritis; TNF

Indexed keywords

CHONDROITIN SULFATE; CHONDROPROTECTIVE AGENT; COLLAGENASE; CORTICOSTEROID; CYTOKINE; DIACETYLRHEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; GLUCOSAMINE; GROWTH FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MINOCYCLINE; NITRIC OXIDE; PIASCLEDINE; PLACEBO; POLYSACCHARIDE; PROSTAGLANDIN E2; RHEIN; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; STROMELYSIN; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ARTICULAR CARTILAGE; AUTOCRINE EFFECT; BONE REMODELING; CARTILAGE CELL; CHONDROPROTECTION; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNEE OSTEOARTHRITIS; NONHUMAN; OSTEOARTHRITIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPONDYLOARTHROPATHY;

ANTIRHEUMATIC AGENTS; CARTILAGE, ARTICULAR; CYTOKINES; GROWTH SUBSTANCES; HUMANS; OSTEOARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 31544479592     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei171     Document Type: Review

References (145)

1. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. ACR subcommittee on osteoarthritis guidelines. Arthritis Rheum 2000;43:1905-15.
2. Chambers MG, Bayliss MT, Mason RM. Chondrocyte cytokine and growth factor expression in murine osteoarthritis. Osteoarthritis Cart 1997;5:301-8.
3. Moos V, Fickert S, Muller B, Weber U, Sieper J. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol 1999;26:870-9.
4. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB. Protection from interleukin 1 induced destruction of articular cartilage by transforming growth factor beta: Studies in anatomically intact cartilage in vitro and in vivo. Ann Rheum Dis 1993; 52:185-91.
5. Guenther HL, Guenther HE, Froesch ER, Fleisch H. Effect of insulin-like growth factor on collagen and glycosaminoglycan synthesis by rabbit articular chondrocytes in culture. Experientia 1982;38:979-81.
6. McQuillan DL, Handley CJ, Campbell MA, Bolis S, Milway VE, Herington AC. Stimulation of proteoglycan synthesis by serum and insulin-like growth factor-1 in cultured bovine articular cartilage. Biochem J 1986;240:423-30.
7. Luyten FP, Hascall VC, Nissley SP, Morales TI, Reddi AH. Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants. Arch Biochem Biophys 1988;267:416-25.
8. Tesch GH, Handley CJ, Cornell HJ, Herington AC. Effects of free and bound insulin-like growth factors on proteoglycan metabolism in articular cartilage explants. J Orthop Res 1992;10:14-22.
9. Verbruggen G, Malfait AM, Dewulf M, Broddelez C, Veys EM. Standardization of nutrient media for isolated human articular chondrocytes in gelified agarose suspension culture. Osteoarthritis Cart 1995;3:249-59.
10. Yaeger PC, Masi TL, de Ortiz JL, Binette F, Tubo R, McPherson JM. Synergistic action of transforming growth factor-beta and insulin-like growth factor-I induces expression of type II collagen and aggrecan genes in adult human articular chondrocytes. Exp Cell Res 1997;237:318-25.
11. Verschure PJ, van Marle J, Joosten LA, van den Berg WB. Chondrocyte IGF-1 receptor expression and responsiveness to IGF-1 stimulation in mouse articular cartilage during various phases of experimentally induced arthritis. Ann Rheum Dis 1995;54:645-53.
12. Saklatvala J, Pilsworth LMC, Sarsfield SJ, Gravilovic J, Heath JK. Pig catabolin is a form of interleukin 1. Biochem J 1984;224:461-6.
13. Dingle JT, Saklatvala J, Hembry R, Tyler J, Fell HB, Jubb R. A cartilage catabolic factor from synovium. Biochem J 1979;184: 177-80.
14. Dingle JT. The effect of synovial catabolin on cartilage synthetic activity. Connect Tiss Res 1984;12:277-86.
15. Tyler JA, Saklatvala J. Pig IL-1 (catabolin) induces resorption of cartilage proteoglycan and prevents synthesis of proteoglycan and collagen. Br J Rheumatol 1985;24(Suppl. 1):150-5.
16. Taskiran D, Stefanovic-Racic M, Georgescu HI, Evans CH. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994;200:142-8.
17. Bird TA, Saklatvala J. Identification of a common class of high affinity receptors for both types of interleukin-1 on connective tissue cells. Nature 1986;324:263-6.
18. Chandrasekhar S, Harvey AK. Induction of interleukin-1 receptors on chondrocytes by fibroblast growth factor: A possible mechanism for modulation of interleukin-1 activity. J Cell Physiol 1989;138: 236-46.
19. Colotta F, Re F, Muzio M et al. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993;261: 472-5.
20. Attur MG, Dave M, Cipolletta C et al. Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem 2000;275:40307-15
21. Wang J, Elewaut D, Veys EM, Verbruggen G. Insulin-like growth factor 1-induced interleukin-1 receptor II overrides the activity of interleukin-1 and controls the homeostasis of the extracellular matrix of cartilage. Arthritis Rheum 2003;48:1281-91.
22. Tyler JA. Insulin-like growth factor 1 can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989;260:543-8.
23. Middleton JF, Tyler JA. Upregulation of insulin-like growth factor I gene expression in the lesions of osteoarthritic human articular cartilage. Ann Rheum Dis 1992;51:440-7.
24. Middleton J, Manthey A, Tyler J. Insulin-like growth factor (IGF) receptor, IGF-I, interleukin-1 beta (IL-1 beta), and IL-6 mRNA expression in osteoarthritic and normal human cartilage. J Histochem Cytochem 1996;44:133-41.
25. Verschure PJ, Marle JV, Joosten LA, Helsen MM, Lafeber FP, Berg WB. Localization of insulin-like growth factor-1 receptor in human normal and osteoarthritic cartilage in relation to proteoglycan synthesis and content. Br J Rheumatol 1996;35:1044-55.
26. Wang J, Verdonk P, Elewaut D, Veys EM, Verbruggen G. Homeostasis of the extracellular matrix of normal and osteoarthritic human articular cartilage chondrocytes in vitro. Osteoarthritis Cart 2003;11:801-9.
27. Shlopov BV, Gumanovskaya ML, Hasty KA. Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis. Arthritis Rheum 2000;43:195-205.
28. Pelletier JP, Martel-Pelletier J, Howell DS, Ghandur-Mnaymneh L, Enis JE, Woessner JF Jr. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 1983;26:63-8.
29. Okada Y, Shinmei M, Tanaka O et al. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest 1992;66:680-90.
30. Arner EC, Tortorella MD. Signal transduction through chondrocyte integrin receptors induces matrix metalloproteinase synthesis and synergizes with interleukin-1. Arthritis Rheum 1995;38:1304-14.
31. Orlando S, Sironi M, Bianchi G et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem 1997;272:31764-9.
32. Penton-Rol G, Orlando S, Polentarutti N et al. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J Immunol 1999;162:2931-8.
33. D'Lima DD, Hashimoto S, Chen PC, Colwell CW Jr, Lotz MK. Human chondrocyte apoptosis in response to mechanical injury. Osteoarthritis Cart 2001;9:712-9.
34. Redman SN, Dowthwaite GP, Thomson BM, Archer CW. The cellular responses of articular cartilage to sharp and blunt trauma. Osteoarthritis Cart 2004;12:106-16.
35. Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in chondrocytes by tumor necrosis factor-α. J Orthop Res 2001;19:785-96.
36. Islam N, Haqqi TM, Jepsen KJ et al. Hydrostatic pressure induces apoptosis in human chondrocytes from osteoarthritic cartilage through up-regulation of tumor necrosis factor-α, inducible nitric oxide synthase, p53, c-myc, and bax-alpha, and suppression of bcl-2. J Cell Biochem 2002;87:266-78.
37. Moos V, Fickert S, Muller B, Weber U, Sieper J. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. J Rheumatol 1999;26:870-9.
38. Verdier MP, Seite S, Guntzer K, Pujol JP, Boumediene K. Immunohistochemical analysis of transforming growth factor beta isoforms and their receptors in human cartilage from normal and osteoarthritic femoral heads. Rheumatol Int 2005;25:118-24.
39. Tchetina EV, Squires G, Poole AR. Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. J Rheumatol 2005; 32:876-86.
40. Harvey AK, Hrubey PS, Chandrasekhar S. Transforming growth factor-beta inhibition of interleukin-1 activity involves down-regulation of interleukin-1 receptors on chondrocytes. Exp Cell Res 1991;195:376-85.
41. Eylau O, Intra-articular heparin therapy of genuine arthrosis deformans of the knee joint. Med Klin 1959;54:145.
42. Eylau O. On the pathogenesis and causal treatment of arthrosis of the knee joint. Med Klin 1960;55:2367-70.
43. Momburg M, Stuhlsatz HW, Vogeli H, Vojtisek O, Eylau O, Greiling H. Clinical chemical changes in the synovial fluid following intra-articular injection of a glycosaminoglycan polysulfate. Z Rheumatol 1976;35(Suppl. 4):389-90.
44. Nevo Z, Horwitz AL, Dorfman A. Synthesis of chondromucoprotein by chondrocytes in suspension culture. Dev Biol 1972;28:219-28.
45. Nevo Z, Dorfman A. Stimulation of chondromucoprotein synthesis in chondrocytes by extracellular chondromucoprotein. Proc Natl Acad Sci USA 1972;69:2069-72.
46. Kosher RA, Lash JW, Minor RR. Environmental enhancement of in vitro chondrogenesis. Dev Biol 1973;35:210-20.
47. Schwartz NB, Dorfman A. Stimulation of chondroitin sulfate proteoglycan production of by chondrocytes in monolayer. Conn Tiss Res 1975;3:115-22.
48. Verbruggen G, Veys EM. Influence of sulphated glycosaminoglycans upon proteoglycan metabolism of the synovial lining cells. Acta Rheumatol 1977;1:75-92.
49. Verbruggen G, Veys EM. Influence of an oversulphated heparinoid upon hyaluronate metabolism of the human synovial cell in vivo. J Rheumatol 1979;6:554-61.
50. Kalbhen DA. Experimental confirmation of the antiarthritic activity of glycosaminoglycan polysulfate. Z Rheumatol 1983;42:178-84.
51. Carreno MR, Muniz OE, Howell DS. The effect of glycosaminoglycan polysulfuric acid ester on articular cartilage in experimental osteoarthritis: Effects on morphological variables of disease severity. J Rheumatol 1986;13:490-7.
52. Brennan JJ, Aherne FX, Nakano T. Effects of glycosaminoglycan polysulfate treatment on soundness, hyaluronic acid content of synovial fluid and proteoglycan aggregate in articular cartilage of lame boars. Can J Vet Res 1987;51:394-8.
53. Uebelhart D, Thonar EJ, Zhang J, Williams JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cart 1998; 6(Suppl. A):6-13.
54. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cart 1998; 6(Suppl. A):37-8.
55. Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002;21:231-43.
56. Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: A pilot study. Osteoarthritis Cart 1998;6(Suppl. A): 39-46.
57. Uebelhart D, Malaise M, Marcolongo R et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cart 2004;12:269-76.
58. Michel BA, Stucki G, Frey D et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum 2005;52:779-86.
59. Verbruggen G, Veys EM. Intra-articular injection of pentosanpoly-sulphate results in increased hyaluronan molecular weight in joint fluid. Clin Exp Rheumatol 1992;10:249-54.
60. Francis DJ, Hutadilok N, Kongtawelert P, Ghosh P. Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo. Rheumatol Int 1993;13:61-4.
61. Verbruggen G, Cornelissen M, Elewaut D, Broddelez C, De Ridder L, Veys EM. Influence of polysulfated polysaccharides on aggrecans synthesized by differentiated human articular chondrocytes. J Rheumatol 1999;26:1663-71.
62. Sadowski T, Steinmeyer J. Effects of polysulfated glycosaminoglycan and triamcinolone acetonid on the production of proteinases and their inhibitors by IL-1alpha treated articular chondrocytes. Biochem Pharmacol 2002;64:217-27.
63. Wang L, Wang J, Almqvist KF, Veys EM, Verbruggen G. Influence of polysulphated polysaccharides and hydrocortisone on the extracellular matrix metabolism of human articular chondrocytes in vitro. Clin Exp Rheumatol 2002;20:669-76.
64. Tung JT, Venta PJ, Caron JP. Inducible nitric oxide expression in equine articular chondrocytes: Effects of antiinflammatory compounds. Osteoarthritis Cart 2002;10:5-12.
65. Verdonk P, Wang J, Elewaut D, Broddelez C, Veys EM, Verbruggen G. Cyclodextrin polysulphates enhance human chondrocyte extracellular matrix repair. Osteoarthritis Cart 2005;13:887-95.
66. Muller W, Panse P, Brand S, Staubli A. In vivo study of the distribution, affinity for cartilage and metabolism of glycosaminoglycan polysulphate (GAGPS, Arteparon). Z Rheumatol 1983;42:355-61.
67. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthritis Cart 2003;11:433-41.
68. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cart 2002;10:768-77.
69. Henrotin YE, Sanchez C, Deberg MA et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003;30:1825-34.
70. Kut-Lasserre C, Miller CC, Ejeil AL et al. Effect of avocado and soybean unsaponifiables on gelatinase A (MMP-2), stromelysin 1 (MMP-3), and tissue inhibitors of matrix metalloproteinase (TIMP-1 and TIMP-2) secretion by human fibroblasts in culture. J Periodontol 2001;72:1685-94.
71. Khayyal MT, el-Ghazaly MA. The possible "chondroprotective" effect of the unsaponifiable constituents of avocado and soya in vivo. Drugs Exp Clin Res 1998;24:41-50.
72. Cake MA, Read RA, Guillou B, Ghosh P. Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). Osteoarthritis Cart 2000;8:404-11.
73. Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural effect of avocado/ soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 2002;47:50-8.
74. Yu LP Jr, Smith GN Jr, Hasty KA, Brandt KD. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991;18: 1450-2.
75. Shlopov BV, Smith GN Jr, Cole AA, Hasty KA. Differential patterns of response to doxycycline and transforming growth factor beta1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum 1999;42:719-27.
76. Shlopov BV, Stuart JM, Gumanovskaya ML, Hasty KA. Regulation of cartilage collagenase by doxycycline. J Rheumatol 2001;28:835-42.
77. Borderie D, Hernvann A, Hilliquin P, Lemarchal H, Kahan A, Ekindjian OG. Tetracyclines inhibit nitrosothiol production by cytokine-stimulated osteoarthritic synovial cells. Inflamm Res 2001;50:409-14.
78. Amin AR, Attur MG, Thakker GD et al. A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996;93:14014-9.
79. Smith GN Jr, Yu LP Jr, Brandt KD, Capello WN. Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. J Rheumatol 1998;25:532-5.
80. Jauernig S, Schweighauser A, Reist M, Von Rechenberg B, Schawalder P, Spreng D. The effects of doxycycline on nitric oxide and stromelysin production in dogs with cranial cruciate ligament rupture. Vet Surg 2001;30:132-9.
81. de Bri E, Lei W, Svensson O, Chowdhury M, Moak SA, Greenwald RA. Effect of an inhibitor of matrix metalloproteinases on spontaneous osteoarthritis in guinea pigs. Adv Dent Res 1998;12:82-5.
82. Yu LP Jr, Smith GN Jr, Brandt KD, Myers SL, O'Connor BL, Brandt DA. Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 1992;35:1150-9.
83. Brandt KD, Mazzuca SA, Katz BP et al. Effects of doxycycline on progression of osteoarthritis: Results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-25.
84. Franchi-Micheli S, Lavacchi L, Friedmann CA, Ziletti L. The influence of rhein on prostaglandin-like substances in vitro. J Pharm Pharmacol 1983;35:262-4.
85. Pomarelli P, Berti M, Gatti MT, Mosconi P. A non-steroidal anti-inflammatory drug that stimulates prostaglandins release. Farmaco Ed Sci 1980;35:836-42.
86. Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol 1998;25:2417-24.
87. Tamura T, Ohmori K. Diacerein suppresses the increase in plasma nitric oxide in rat adjuvant-induced arthritis. Eur J Pharmacol 2001;419:269-74.
88. 2 production independent of its effect on nitric oxide. J Immunol 1999;162:3160-7.
89. Patel RN, Attur MG, Dave MN et al. A novel mechanism of action of chemically modified tetracyclines: Inhibition of COX-2-mediated prostaglandin E2 production. Immunology 1999;163:3459-67.
90. Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cart 1999;7:272-80.
91. Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol 1998;25:753-62.
92. Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cart 2000;8:186-96.
93. Mendes AF, Caramona MM, de Carvalho AO, Lopes MC. Diacerhein and rhein prevent interleukin-1beta-induced nuclear factor-kappaB activation by inhibiting the degradation of inhibitor kappaB-alpha. Pharmacol Toxicol 2002;91:22-8.
94. Dozin B, Malpeli M, Camardella L, Cancedda R, Pietrangelo A. Response of young, aged and osteoarthritic human articular chondrocytes to inflammatory cytokines: Molecular and cellular aspects. Matrix Biol 2002;21:449-59.
95. Boittin N, Redini F, Loyau G, Pujol JP. Effect of diacerhein (ART 50) on the matrix synthesis and collagenase secretion by cultured joint chondrocytes in rabbits. Rev Rhum 1993;60:68S-76S.
96. Tamura T, Kosaka N, Ishiwa J, Sato T, Nagase H, Ito A. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis Cart 2001;9:257-63.
97. Tamura T, Ohmori K. Rhein, an active metabolite of diacerein, suppresses the interleukin-1alpha-induced proteoglycan degradation in cultured rabbit articular chondrocytes. Jpn J Pharmacol 2001; 85:101-4.
98. Felisaz N, Boumediene K, Ghayor C et al. Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cart 1999;7:255-64.
99. Mazieres B, Berdah L, Thiechart M, Viguier G. Diacetylrhein on a postcontusion model of experimental osteoarthritis in the rabbit. Rev Rhum 1993;60:77S-81S.
100. Tamura T, Ohmori K, Nakamura K. Effect of diacerein on spontaneous polyarthritis in male New Zealand black/KN mice. Osteoarthritis Cart 1999;7:533-8.
101. Carney SL. Effect of diacetyl rhein on the development of experimental osteoarthritis. A biochemical investigation. Osteoarthritis Cart 1996;4:251-61.
102. Brandt KD, Smith G, Kang SY, Myers S, O'Connor B, Albrecht N. Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthritis Cart 1997;5:438-49.
103. Smith GN Jr, Myers SL, Brandt KD, Mickler EA, Albrecht ME. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum 1999;42:545-54.
104. Dougados M, Nguyen M, Berdah L, Mazieres B, Lequesne M; ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001;44:2539-47.
105. Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis 2004;63:1611-7.
106. Gouze JN, Bianchi A, Becuwe P et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett 2002;510:166-70.
107. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol 2001;166:5155-60.
108. Largo R, Alvarez-Soria MA, Diez-Ortego I et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cart 2003;11:290-8.
109. Piperno M, Reboul P, Hellio Le Graverand MP et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cart 2000;8:207-12.
110. Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 2004; 22:293-9.
111. Gouze JN, Bordji K, Gulberti S et al. Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: Influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum 2001;44:351-60.
112. Fenton JI, Chlebek-Brown KA, Caron JP, Orth MW. Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine Vet J Suppl 2002;34:219-23.
113. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cart 2000;8:258-65.
114. Tung JT, Venta PJ, Eberhart SW, Yuzbasiyan-Gurkan V, Alexander L, Caron JP. Effects of anti-arthritis preparations on gene expression and enzyme activity of cyclooxygenase-2 in cultured equine chondrocytes. Am J Vet Res 2002;63:1134-9.
115. Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cart 2003;11:424-32.
116. Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: Aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998;335:59-66.
117. Patwari P, Kurz B, Sandy JD, Grodzinsky AJ. Mannosamine inhibits aggrecanase-mediated changes in the physical properties and biochemical composition of articular cartilage. Arch Biochem Biophys 2000;374:79-85.
118. de Mattei M, Pellati A, Pasello M et al. High doses of glucosamine-HCl have detrimental effects on bovine articular cartilage explants cultured in vitro. Osteoarthritis Cart 2002;10:816-25.
119. Tiraloche G, Girard C, Chouinard L et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum 2005;52:1118-28.
120. Shikhman AR, Amiel D, D'Lima D et al. Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis. Ann Rheum Dis 2005;64:89-94.
121. Reginster JY, Deroisy R, Rovati LC et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
122. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002;162:2113-23.
123. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 1987;139:4129-34.
124. Lee SW, Tsou AP, Chan H et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. Proc Natl Acad Sci USA 1988;85:1204-8.
125. Pelletier JP, Cloutier JM, Martel-Pelletier J. In vitro effects of tiaprofenic acid, sodium salicylate and hydrocortisone on the proteoglycan metabolism of human osteoarthritic cartilage. J Rheumatol 1989;16:646-55.
126. Hill DJ. Effects of cortisol on cell proliferation and proteoglycan synthesis and degradation in cartilage zones of the calf costochondral growth plate in vitro with and without rat plasma somatomedin activity. J Endocrinol 1981;88:425-35.
127. Takigawa M, Takano T, Nakagawa K, Sakuda M, Suzuki F. Hydrocortisone stimulation of proliferation and glycosaminoglycan synthesis in rabbit craniofacial chondrocytes in vitro. Arch Oral Bio1 1988;33:893-9.
128. McGuire MB, Murphy M, Reynolds JJ, Russell RGG. Production of collagenase and inhibitor (TIMP) by normal, rheumatoid and osteoarthritic synovium in vitro: Effects of hydrocortisone and indomethacin. Clin Biol 1981;61:703-10.
129. Pelletier JP, Martel-Pelletier J. Cartilage degradation by neutral proteoglycanases in experimental osteoarthritis. Suppression by steroids. Arthritis Rheum 1985;28:1393-401.
130. Martel-Pelletier J, Cloutier JM, Pelletier JP. Neutral proteases in human osteoarthritic synovium. Arthritis Rheum 1986;29: 1112-21.
131. Pelletier JP, Martel-Pelletier J, Cloutier JM, Woessner JF Jr. Proteoglycan-degrading acid metalloproteinase activity in human osteoarthritic cartilage, and the effects of intraarticular steroid injections. Arthritis Rheum 1987;30:541-8.
132. Pelletier JP, Mineau F, Raynauld JP, Woessner JF, Gunja-Smith Z, Martel-Pelletier J. Intraarticular injections with methylprednisolone acetate reduce osteoarthritic lesions in parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis. Arthritis Rheum 1994;37:414-23.
133. Itagane Y, Inada H, Fujita K, Isshiki G. Interactions between steroid hormones and insulin-like growth factor-I in rabbit chondrocytes. Endocrinology 1991;128:1419-24.
134. Van der Kraan PM, Vitters EL, Postma NS, Verbunt J, van den Berg WB. Maintenance of the synthesis of large proteoglycans in anatomically intact murine articular cartilage by steroids and insulin-like growth factor I. Ann Rheum Dis 1993; 52:734-41.
135. Van Osch GJ, van der Veen SW, Verwoerd-Verhoef HL. In vitro redifferentiation of culture-expanded rabbit and human auricular chondrocytes for cartilage reconstruction. Plast Reconstr Surg 2001;107:433-40.
136. Colombo C, Butler M, Hickman L, Selwyn M, Chart J, Steinetz B. A new model of osteoarthritis in rabbits. II. Evaluation of anti-osteoarthritic effects of selected antirheumatic drugs administered systemically. Arthritis Rheum 1983;26:1132-9.
137. Butler M, Colombo C, Hickman L et al. A new model of osteoarthritis in rabbits. III. Evaluation of anti-osteoarthritic effects of selected drugs administered intraarticularly. Arthritis Rheum 1983;26:1380-6.
138. Williams JM, Brandt KD. Triamcinolone hexacetonide protects against fibrillation and osteophyte formation following chemically induced articular cartilage damage. Arthritis Rheum 1985;28: 1267-74.
139. Pelletier JP, Martel-Pelletier J. Protective effects of corticosteroids on cartilage lesions and osteophyte formation in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum 1989;32:181-93.
140. Wang J, Elewaut D, Hoffman I, Veys EM, Verbruggen G. Physiological levels of hydrocortisone maintain an optimal chondrocyte extracellular matrix metabolism. Ann Rheum Dis 2004;63:61-6.
141. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2:244-7.
142. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343: 1594-602.
143. Smolen JS, Han C, Bala M et al.; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
144. Kruithof E, Van den Bosch F, Baeten D et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: One year follow up. Ann Rheum Dis 2002;61:207-12.
145. Verbruggen G, Veys EM. Numerical scoring systems for the anatomic evolution of osteoarthritis of the finger joints. Arthritis Rheum 1996;39:308-20.